Singular Genomics Systems Stock Revenue
| OMICDelisted Stock | USD 20.01 0.00 0.00% |
Singular Genomics Systems fundamentals help investors to digest information that contributes to Singular Genomics' financial success or failures. It also enables traders to predict the movement of Singular Stock. The fundamental analysis module provides a way to measure Singular Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Singular Genomics stock.
Singular |
Singular Genomics Systems Company Revenue Analysis
Singular Genomics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Singular Genomics Revenue | 2.91 M |
Most of Singular Genomics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Singular Genomics Systems is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Singular Genomics Systems reported 2.91 M of revenue. This is 99.96% lower than that of the Health Care Equipment & Supplies sector and 99.84% lower than that of the Health Care industry. The revenue for all United States stocks is 99.97% higher than that of the company.
Singular Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Singular Genomics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Singular Genomics could also be used in its relative valuation, which is a method of valuing Singular Genomics by comparing valuation metrics of similar companies.Singular Genomics is currently under evaluation in revenue category among its peers.
Singular Fundamentals
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (44.51) % | ||||
| Current Valuation | (12.58 M) | ||||
| Shares Outstanding | 2.54 M | ||||
| Shares Owned By Insiders | 14.10 % | ||||
| Shares Owned By Institutions | 54.80 % | ||||
| Number Of Shares Shorted | 44.74 K | ||||
| Price To Earning | 35.71 X | ||||
| Price To Book | 0.41 X | ||||
| Price To Sales | 19.03 X | ||||
| Revenue | 2.91 M | ||||
| Gross Profit | (1.35 M) | ||||
| EBITDA | (86.5 M) | ||||
| Net Income | (94.82 M) | ||||
| Cash And Equivalents | 287.98 M | ||||
| Cash Per Share | 4.05 X | ||||
| Total Debt | 75.29 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 22.98 X | ||||
| Book Value Per Share | 49.16 X | ||||
| Cash Flow From Operations | (73.65 M) | ||||
| Short Ratio | 4.34 X | ||||
| Earnings Per Share | (34.68) X | ||||
| Price To Earnings To Growth | (0.15) X | ||||
| Target Price | 12.45 | ||||
| Number Of Employees | 255 | ||||
| Beta | 1.84 | ||||
| Market Capitalization | 50.77 M | ||||
| Total Asset | 265.47 M | ||||
| Retained Earnings | (337.6 M) | ||||
| Working Capital | 173.94 M | ||||
| Net Asset | 265.47 M |
About Singular Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Singular Genomics Systems's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Singular Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Singular Genomics Systems based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Singular Stock
If you are still planning to invest in Singular Genomics Systems check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Singular Genomics' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| CEOs Directory Screen CEOs from public companies around the world |